Ovarian cancer

You have access
IMP3 Expression in Borderline Tumors of the Ovary
AHMED EL-BALAT, NICOLE SÄNGER, THOMAS KARN, SVEN BECKER, UWE HOLTRICH, ZELAL MUALLEM and RUZA ARSENIC

Anticancer Research February 2017, 37 (2) 583-588;
You have access
Implementing the Risk of Ovarian Malignancy Algorithm Adding Obesity as a Predictive Factor
EMANUELA ANASTASI, DANILA CAPOCCIA, TERESA GRANATO, GIANFRANCO SILECCHIA, MARIO RIZZELLO, MARIA GRAZIA PORPORA, LUIGI FRATI, ANTONIO ANGELONI and FRIDA LEONETTI

Anticancer Research December 2016, 36 (12) 6425-6429;
You have access
The Effects of Histone Deacetylase Inhibitor and Calpain Inhibitor Combination Therapies on Ovarian Cancer Cells
KAROLINA LAPINSKA, GENEVIEVE HOUSMAN, SHANNON BYLER, SARAH HEERBOTH, AMBER WILLBANKS, ANUJA OZA and SIBAJI SARKAR

Anticancer Research November 2016, 36 (11) 5731-5742;
You have access
The Use of Toll-like Receptor 4 Agonist to Reshape the Immune Signature in Ovarian Cancer
EVA VINDEVOGEL, THAÏS BAERT, ANAÏS VAN HOYLANDT, GODELIEVE VERBIST, GREETJE VANDE VELDE, ABHISHEK D. GARG, PATRICIA AGOSTINIS, IGNACE VERGOTE and AN COOSEMANS

Anticancer Research November 2016, 36 (11) 5781-5792;
You have access
Podoplanin as Key Player of Tumor Progression and Lymph Vessel Proliferation in Ovarian Cancer
IONUT MARCEL COBEC, IOAN SAS, LAURENȚIU PIRTEA, ANCA MARIA CIMPEAN, AURICA ELISABETA MOATAR, RALUCA AMALIA CEAUȘU and MARIUS RAICA

Anticancer Research October 2016, 36 (10) 5265-5272;
You have access
What Characterizes Long-term Survivors of Recurrent Ovarian Cancer? Case Report and Review of the Literature
ZIAD HILAL, BEATE SCHULTHEIS, FRANZISKA HARTMANN, ASKIN DOGAN, CEM CETIN, HARALD KRENTEL, SVEN SCHIERMEIER and CLEMENS B. TEMPFER

Anticancer Research October 2016, 36 (10) 5365-5371;
You have access
The Influence of Cyst Emptying, Lymph Node Resection and Chemotherapy on Survival in Stage IA and IC1 Epithelial Ovarian Cancer
MIKKEL ROSENDAHL, BERIT JUL MOSGAARD and CLAUS HØGDALL

Anticancer Research October 2016, 36 (10) 5373-5379;
You have access
Bevacizumab for Ovarian Cancer at High Risk of Progression: Reproducibility of Trial Results in ‘Real-world’ Patients
GIANFILIPPO BERTELLI, FLORIAN DREWS and KERRYN LUTCHMAN-SINGH

Anticancer Research September 2016, 36 (9) 4947-4950;
You have access
Flow Cytometric Analysis of Ovarian Cancer Ascites: Response of Mesothelial Cells and Macrophages to Cancer
KAZUNORI HASHIMOTO, KAZUHO HONDA, HIDEO MATSUI, YOJI NAGASHIMA and HIDEAKI ODA

Anticancer Research July 2016, 36 (7) 3579-3584;
You have access
Drug-induced Modulation of Heat Shock Protein HSPB1 in an Ovarian Cancer Cell Model
MATTHIAS B. STOPE, LUISE WIEGANK, MARTIN WEISS, KAROLINE DIESING, DOMINIQUE KOENSGEN, MARTIN BURCHARDT, MAREK ZYGMUNT and ALEXANDER MUSTEA

Anticancer Research July 2016, 36 (7) 3321-3327;

Main menu

User menu

Search

Ovarian cancer

Pages